AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Cancer
Locally Advanced
Metastatic Solid Tumors
Lung Cancers
Epithelial Tumor
Biliary Tract Cancer (BTC)
Urothelial Cancer
Nasopharyngeal Cancers

Interventions

DRUG: AVZO-1418
DRUG: Combination Agent 1
DRUG: Combination Agent 2

Sponsor

Avenzo Therapeutics, Inc.